哈三联涨2.10%，成交额4103.33万元，主力资金净流入46.33万元

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has shown a mixed performance in stock price and financial results, with a notable increase in stock price year-to-date but significant declines in revenue and net profit for the recent period [1][2]. Group 1: Stock Performance - As of December 18, Harbin Sanlian's stock price increased by 2.10% to 13.15 CNY per share, with a trading volume of 41.03 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 4.16 billion CNY [1]. - Year-to-date, the stock price has risen by 36.27%, but it has experienced a decline of 1.79% over the last five trading days, 4.29% over the last 20 days, and 4.15% over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a stock market leaderboard) nine times this year, with the most recent appearance on June 3 [1]. Group 2: Financial Performance - For the period from January to September 2025, Harbin Sanlian reported a revenue of 581 million CNY, representing a year-on-year decrease of 30.75%, and a net profit attributable to shareholders of -209 million CNY, a significant decline of 614.61% [2]. - The number of shareholders as of December 10 is 38,100, which is a decrease of 4.00% from the previous period, while the average number of circulating shares per person increased by 4.16% to 4,594 shares [2]. Group 3: Business Overview - Harbin Sanlian, established on June 21, 1996, and listed on September 22, 2017, is primarily engaged in the research, production, and sales of chemical drug formulations [1]. - The revenue composition of the company includes: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments [1]. - The company operates within the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors such as hypertension treatment, anti-influenza, hepatitis treatment, innovative drugs, and pet economy [1]. Group 4: Dividend Information - Since its A-share listing, Harbin Sanlian has distributed a total of 677 million CNY in dividends, with 158 million CNY distributed over the past three years [3].